Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 20/20 | 0.50 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.50 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17907967 | 0.92 | PTGDR2 (0.59) | PTGDR2TBXA2RPTGDRCYP2C9KCNH2 | |
| SCHEMBL17907926 | 0.88 | PTGDR2 (0.47) | PTGDR2TBXA2RPTGDRSLC6A3 | |
| SCHEMBL17907966 | 0.88 | PTGDR2 (0.51) | PTGDR2TBXA2RPTGDR | |
| SCHEMBL17907960 | 0.88 | PTGDR2 (0.49) | PTGDR2TBXA2RPTGDR | |
| SCHEMBL17907923 | 0.85 | PTGDR2 (0.53) | PTGDR2TBXA2RPTGDR | |
| SCHEMBL17907989 | 0.85 | PTGDR2 (0.52) | PTGDR2TBXA2RPTGDRSLC6A3CYP2C9 | |
| SCHEMBL13278753 | 0.81 | PTGDR2 (0.59) | PTGDR2TBXA2RPTGDR | |
| SCHEMBL13278879 | 0.81 | PTGDR2 (0.59) | PTGDR2TBXA2RPTGDR | |
| SCHEMBL13278751 | 0.81 | PTGDR2 (0.59) | PTGDR2TBXA2RPTGDR | |
| SCHEMBL17907972 | 0.81 | PTGDR2 (0.52) | PTGDR2TBXA2RPTGDRCYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2697223-B1 | 7-(HETEROARYL-AMINO)-6,7,8,9-TETRAHYDROPYRIDO[1,2-A]INDOL ACETIC ACID DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-07-13 | — | — | EP | disclosed |